Redeye leaves a comment on Xbrane’s press release stating that it now has re-submitted its Lucentis biosimilar’s BLA to the FDA. With expected 6-month review time a new BsUFA date is anticipated by mid-2025.
ANNONS
Redeye leaves a comment on Xbrane’s press release stating that it now has re-submitted its Lucentis biosimilar’s BLA to the FDA. With expected 6-month review time a new BsUFA date is anticipated by mid-2025.